124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trialMafalda Oliveira, Aleix Prat, Claudette Falato et al.|ESMO Open|2023Cited by 8
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trialMafalda Oliveira, Aleix Prat, Tomás Pascual et al.|ESMO Open|2023Cited by 6
13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratificationRodrigo Sánchez-Bayona, Eva Ciruelos, O. Martínez-Sáez et al.|ESMO Open|2024Cited by 1
248P Real-world relapse-free survival in HR+/HER2- breast cancer with PAM50 intermediate-risk groupSantiago Terán, Rodrigo Sánchez-Bayona, M. Quevedo et al.|ESMO Open|2025Cited by 0
38P Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a global data networkL.M. Manso Sànchez, L. Paz-Ares, A. Madariaga Urrutia et al.|Annals of Oncology|2022Cited by 0